https://www.selleckchem.com/products/ap20187.html
2 ± 5.4 days vs. 32.2 ± 7.8 days; p less then 0.05), reduced major limb amputation rate (1.4% vs. 10.4%, p less then 0.05), and ulcer recurrence rate (5.6% vs. 14.6%; p less then 0.05). There were no significant differences in amputation rate between experimental and control group (29.2% vs. 33.3%, p = 0.628). After revascularization, the revascularization group showed significantly improved ABI (0.75 ± 0.21 vs. 0.35 ± 0.16, p less then 0.05) and TcPO2 (36 ± 6 mmHg vs. 15 ± 4 mmHg, p less then 0.05). #link# Innovation We propo
Like
Comment
Share
